Tiziana seeks FDA orphan drug designation for intranasal foralumab in multiple system atrophy

PUBT · 2d ago
Tiziana seeks FDA orphan drug designation for intranasal foralumab in multiple system atrophy
  • Tiziana Life Sciences filed with the FDA for orphan drug designation for intranasal foralumab to treat multiple system atrophy.
  • FDA typically reviews orphan designation requests within 90 days; a grant would confer incentives such as market exclusivity upon approval.
  • Intranasal foralumab is in a Phase 2a open-label MSA trial at Brigham and Women’s Hospital under Mass General Brigham’s MyTrial program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300700OMX_____CNEWS_EN_GNW9836788_en) on September 30, 2026, and is solely responsible for the information contained therein.